Immune checkpoint inhibitors and SARS-CoV2 infection
File(s)
Accepted version
Author(s)
Abdolmohammadi-Vahid, Samaneh
Baradaran, Behzad
Adcock, Ian
Mortaz, Esmaeil
Type
Journal Article
Abstract
Infection with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) triggers coronavirus disease 2019 (COVID-19), which predominantly targets the respiratory tract. SARS-CoV-2 infection, especially severe COVID-19, is associated with dysregulated immune responses against the virus, including exaggerated inflammatory responses known as the cytokine storm, together with lymphocyte and NK cell dysfunction known as immune cell exhaustion. Overexpression of negative immune checkpoints such as PD-1 and CTLA-4 plays a considerable role in the dysfunction of immune cells upon SARS-CoV-2 infection. Blockade of these checkpoints has been suggested to improve the clinical outcome of COVID-19 patients by promoting potent immune responses against the virus. In the current review, we provide an overview of the potential of checkpoint inhibitors to induce potent immune responses against SARS-CoV-2 and improving the clinical outcome of severe COVID-19 patients.
Date Issued
2024-08-20
Date Acceptance
2024-02-06
Citation
International Immunopharmacology, 2024, 137
ISSN
1567-5769
Publisher
Elsevier
Journal / Book Title
International Immunopharmacology
Volume
137
Copyright Statement
© 2024 Published by Elsevier B.V. All rights are reserved. This is the author’s accepted manuscript made available under a CC-BY licence in accordance with Imperial’s Research Publications Open Access policy (www.imperial.ac.uk/oa-policy)
License URL
Publication Status
Published
Article Number
112419
Date Publish Online
2024-06-11